DUBLIN – Shares in Geneuro SA fell more than 16 percent Tuesday on news that Les Laboratoires Servier SAS decided not to trigger an option to take forward GNbAC1, a first-in-class antibody that has completed a phase IIb trial in multiple sclerosis (MS).